Repligen Co. (NASDAQ:RGEN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Repligen Co. (NASDAQ:RGEN) have been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $193.00.

RGEN has been the subject of several recent analyst reports. JPMorgan Chase & Co. lowered their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Guggenheim initiated coverage on shares of Repligen in a report on Tuesday, June 18th. They set a “neutral” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and reduced their price target for the company from $180.00 to $155.00 in a report on Wednesday, June 26th.

Insider Activity at Repligen

In other Repligen news, CEO Anthony Hunt sold 20,072 shares of the stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the sale, the chief executive officer now owns 163,177 shares in the company, valued at $27,456,162.02. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Repligen news, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now owns 163,177 shares in the company, valued at $27,456,162.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Martin D. Madaus acquired 1,615 shares of the business’s stock in a transaction dated Friday, June 14th. The stock was acquired at an average cost of $124.94 per share, with a total value of $201,778.10. Following the completion of the transaction, the director now owns 4,613 shares of the company’s stock, valued at $576,348.22. The disclosure for this purchase can be found here. 1.20% of the stock is owned by company insiders.

Institutional Trading of Repligen

A number of hedge funds have recently modified their holdings of RGEN. Envestnet Portfolio Solutions Inc. acquired a new stake in Repligen during the third quarter worth approximately $585,000. Envestnet Asset Management Inc. lifted its holdings in Repligen by 39.7% during the 3rd quarter. Envestnet Asset Management Inc. now owns 106,379 shares of the biotechnology company’s stock worth $16,915,000 after purchasing an additional 30,239 shares during the last quarter. Northern Trust Corp boosted its stake in Repligen by 2.4% in the 3rd quarter. Northern Trust Corp now owns 471,919 shares of the biotechnology company’s stock valued at $75,040,000 after purchasing an additional 11,204 shares during the period. Natixis Advisors L.P. grew its holdings in Repligen by 9.2% in the 3rd quarter. Natixis Advisors L.P. now owns 28,835 shares of the biotechnology company’s stock valued at $4,585,000 after buying an additional 2,436 shares in the last quarter. Finally, Primecap Management Co. CA increased its position in Repligen by 6.9% during the 3rd quarter. Primecap Management Co. CA now owns 50,629 shares of the biotechnology company’s stock worth $8,051,000 after buying an additional 3,250 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN stock opened at $126.06 on Wednesday. The stock has a market cap of $7.04 billion, a PE ratio of 504.26, a price-to-earnings-growth ratio of 4.21 and a beta of 1.04. The stock has a 50-day moving average of $151.71 and a 200-day moving average of $173.93. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. Repligen has a one year low of $110.45 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The firm had revenue of $151.31 million during the quarter, compared to the consensus estimate of $150.06 million. During the same period in the previous year, the company posted $0.64 EPS. The firm’s revenue for the quarter was down 17.1% on a year-over-year basis. As a group, sell-side analysts expect that Repligen will post 1.46 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.